Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on April 29, 2025
Milliways, la révolution du chewing-gum, débarque en France
GlobeNewswire
·
April 29, 2025
Milliways, la marque britannique de chewing-gum sans plastique en pleine expansion, annonce son lancement en France avec l’ambition de transformer un marché resté figé depuis des décennies. Déjà leader de la catégorie “plastic-free” au Royaume-Uni, …
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress
GlobeNewswire
·
April 29, 2025
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene …
Aveanna to Participate at the RBC 2025 Global Healthcare Conference
GlobeNewswire
·
April 29, 2025
ATLANTA, April 29, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the RBC 2025 Global Healthcare Conference in New York on May 20, 2025. Management will host 1x1 …
Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy
GlobeNewswire
·
April 29, 2025
– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer – – TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall …
Atsena Therapeutics to Present at May Scientific Conferences
GlobeNewswire
·
April 29, 2025
DURHAM, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced it will present at the following …
Repligen Reports First Quarter 2025 Financial Results
GlobeNewswire
·
April 29, 2025
Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growth Orders increased sequentially and high-teens year-over-year Adjusted operating income increased 72% year-over-year Reiterates 2025 full year organic …
Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast
GlobeNewswire
·
April 29, 2025
SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter …
Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)
GlobeNewswire
·
April 29, 2025
twiist™ expands compatibility offerings to become the first AID system compatible with Senseonics Eversense® 365 one-year CGM system twiist with Eversense 365 launch expected in Q3 MANCHESTER, N.H. and GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- …
Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)
GlobeNewswire
·
April 29, 2025
twiist™ expands compatibility offerings to become the first AID system compatible with Senseonics Eversense® 365 one-year CGM system twiist with Eversense 365 launch expected in Q3 MANCHESTER, N.H. and GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- …
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients
GlobeNewswire
·
April 29, 2025
MIAMI, April 29, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of …
Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
GlobeNewswire
·
April 29, 2025
WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, M.D. has …
Oxford-Harrington Rare Disease Centre Appoints Majid Jafar to its Advisory Council
GlobeNewswire
·
April 29, 2025
Mr. Jafar is a distinguished international business leader and co-founder of the Loulou Foundation OXFORD, UK and CLEVELAND, Ohio, US, 29 April 2025 – The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the University of Oxford, UK and …
Dianthus Therapeutics to Participate in Two Upcoming Investor Events
GlobeNewswire
·
April 29, 2025
NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune …
Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference
GlobeNewswire
·
April 29, 2025
MENLO PARK, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including …
Option Care Health Announces Financial Results for the First Quarter Ended March 31, 2025
GlobeNewswire
·
April 29, 2025
BANNOCKBURN, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results …
Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States
GlobeNewswire
·
April 29, 2025
CLN-978 is the first and only development-stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases Sjögren’s disease represents the third indication under development for CLN-978, and is a disease with high unmet need and no …
Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences
GlobeNewswire
·
April 29, 2025
BEDFORD, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific …
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
GlobeNewswire
·
April 29, 2025
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025 Digestive Disease Week (DDW) Conference …
Skye Bioscience to Participate in May Investment and Medical Conferences
GlobeNewswire
·
April 29, 2025
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will …
EsoBiotec to Present Preclinical Proof-of-Concept Data for Its Off-the-Shelf ENaBL In Vivo Cell Therapy Platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy
GlobeNewswire
·
April 29, 2025
Poster talk will present safety and efficacy data for ENaBL-T, a lentiviral vector for in vivo engineering of BCMA CAR T cells, which supported the first in vivo BCMA CAR-T cell therapy clinical trial for patients with relapse or refractory multiple …